Impact of trough plasma imatinib levels on patients with suboptimal responses after treatment with standard dose of imatinib in chronic-phase chronic myelogenous leukemia

江浩,陈珊珊,黄晓军,秦亚溱,赖悦云,秦效英,江滨

2012-01-01

Abstract:Objective To evaluated the impact of trough plasma imatinib levels on patients with suboptimal responses after treatment with standard dose of imatinib in chronic-phase chronic myelogenous leukemia(CML-CP).Methods We measured trough IM levels in 55 patients with CML-CP at 3,6 months or post 12 months after treatment imatinib.Trough IM levels were detected again in patients with suboptimal response who received increased dose of imatinib for 3 and 6 months.Results Trough IM levels were(1685±637)μg/L in patients with 400 mg/d imatinib.Trough IM levels were significantly higher(1881±669)μg/L in patients who achieved a major molecular response(MMR)after treatment with standard dose of imatinib for 18 months than in those who did not(1262±346)μg/L.Among 17 patients who did not achieve MMR at 18 months after treatment,6(86%)patients who recieved imatinib to 600 mg/d for median 9 months achieved MMR,however,3(30%)patients who continued to treat with standard dose of imatinib achieved MMR(P=0.05).Conclusion Trough IM levels are correlated with optimal molecular response at 18 months after treatment with standard dose of imatinib in CML-CP.Dose escalation of IM can increase trough IM levels and molecular response in patients with CML-CP showing suboptimal response.